PE20020424A1 - PROCEDURE FOR THE PREPARATION OF POWDER FORMULATIONS - Google Patents

PROCEDURE FOR THE PREPARATION OF POWDER FORMULATIONS

Info

Publication number
PE20020424A1
PE20020424A1 PE2001001002A PE2001001002A PE20020424A1 PE 20020424 A1 PE20020424 A1 PE 20020424A1 PE 2001001002 A PE2001001002 A PE 2001001002A PE 2001001002 A PE2001001002 A PE 2001001002A PE 20020424 A1 PE20020424 A1 PE 20020424A1
Authority
PE
Peru
Prior art keywords
particle size
active principle
substance
procedure
preparation
Prior art date
Application number
PE2001001002A
Other languages
Spanish (es)
Inventor
Michael Walz
Georg Boeck
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26007343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020424(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2001138022 external-priority patent/DE10138022A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20020424A1 publication Critical patent/PE20020424A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)

Abstract

SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE FORMULACIONES EN POLVOS DE INHALACION, CARACTERIZADO PORQUE N+m PORCIONES DE APROXIMADAMENTE IGUAL TAMANO DE SUSTANCIA CON UNA DISTRIBUCION MAYOR DEL TAMANO DE PARTICULAS (COADYUVANTE) Y N PORCIONES DE IGUAL TAMANO DE UNA SUSTANCIA CON UNA DISTRIBUCION MENOR DEL TAMANO DE PARTICULAS (PRINCIPIO ACTIVO) SE ANADEN DE FORMA INTERMITENTE EN CAPAS POR MEDIO DE UN DISPOSITIVO DE TAMIZADO ADECUADO A UN RECIPIENTE DE MEZCLA Y, DESPUES DE LA ADICION COMPLETA , LAS 2N+m CAPAS DE LOS DOS COMPONENTES SE MEZCLAN EFECTUANDOSE PRIMERAMENTE LA ADICION DE UNA PORCION DE LA SUSTANCIA CON UN TAMANO DE PARTICULAS MAYOR SIENDO N UN NUMERO ENTERO MAYOR QUE 0 PREFERIBLEMENTE MAYOR QUE 5 Y m ES 0-1. SE OBTIENEN POLVOS DE INHALACION QUE CONTIENEN MENOS DE 5% DE PREFERENCIA 2% DEL PRINCIPIO ACTIVO. EL PRINCIPIO ACTIVO PRESENTA UN TAMANO DE PARTICULAS DE 0,5um A 10 um, EL COADYUVANTE UTILIZADO TIENE UN TAMANO MEDIO DE 10 A 100um. EL PRINCIPIO ACTIVO SE SELECCIONADA DE COMPUESTOS BETAMIMETICOS, ANTICOLINERGICOS, CORTICOSTEROIDES Y AGONISTAS DE DOPAMINAIT REFERS TO A PROCEDURE FOR THE PREPARATION OF FORMULATIONS IN INHALATION POWDERS, CHARACTERIZED BY N + m PORTIONS OF APPROXIMATELY THE SIZE OF SUBSTANCE WITH A HIGHER DISTRIBUTION OF THE PARTICLE SIZE (COADJUVANT) AND N PORTIONS OF THE SAME SUBSTANCE THE PARTICLE SIZE (ACTIVE PRINCIPLE) ARE INTERMITTENTLY ADDED IN LAYERS BY MEANS OF A SUITABLE SCREENING DEVICE TO A MIXING VESSEL AND, AFTER COMPLETE ADDITION, THE 2N + m LAYERS OF THE TWO COMPONENTS ARE MIXED FIRST. ADDITION OF A PORTION OF THE SUBSTANCE WITH A GREATER PARTICLE SIZE WHERE N IS AN INTEGRAL NUMBER GREATER THAN 0, PREFERABLY GREATER THAN 5 AND m IS 0-1. INHALATION POWDERS ARE OBTAINED THAT CONTAIN LESS THAN 5%, PREFERENCING 2% OF THE ACTIVE PRINCIPLE. THE ACTIVE PRINCIPLE HAS A PARTICLE SIZE FROM 0.5um TO 10 um, THE ADJUVANT USED HAS A MEDIUM SIZE OF 10 TO 100um. THE ACTIVE PRINCIPLE IS SELECTED FROM BETAMIMETIC COMPOUNDS, ANTICHOLINERGICS, CORTICOSTEROIDS AND DOPAMINE AGONISTS

PE2001001002A 2000-10-12 2001-10-10 PROCEDURE FOR THE PREPARATION OF POWDER FORMULATIONS PE20020424A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10050635 2000-10-12
DE2001138022 DE10138022A1 (en) 2001-08-10 2001-08-10 Production of homogeneous inhalation powders comprises introducing alternate layers of large excipient particles and small drug particles into a mixing vessel

Publications (1)

Publication Number Publication Date
PE20020424A1 true PE20020424A1 (en) 2002-07-02

Family

ID=26007343

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001001002A PE20020424A1 (en) 2000-10-12 2001-10-10 PROCEDURE FOR THE PREPARATION OF POWDER FORMULATIONS

Country Status (40)

Country Link
US (2) US6585959B2 (en)
EP (1) EP1326585B2 (en)
JP (2) JP4986369B2 (en)
KR (1) KR100849837B1 (en)
CN (1) CN1269470C (en)
AR (1) AR034166A1 (en)
AT (1) ATE319422T1 (en)
AU (2) AU1822002A (en)
BG (1) BG66194B1 (en)
BR (1) BR0114316A (en)
CA (1) CA2425005C (en)
CY (1) CY1105037T1 (en)
CZ (1) CZ300022B6 (en)
DE (1) DE50109178D1 (en)
DK (1) DK1326585T4 (en)
EA (1) EA004689B1 (en)
EE (1) EE05146B1 (en)
EG (1) EG24478A (en)
ES (1) ES2259046T5 (en)
HK (1) HK1060522A1 (en)
HR (1) HRP20030277B1 (en)
HU (1) HU229512B1 (en)
IL (2) IL154919A0 (en)
ME (1) ME02762B (en)
MX (1) MXPA03003219A (en)
MY (1) MY155912A (en)
NO (1) NO333719B1 (en)
NZ (1) NZ525781A (en)
PE (1) PE20020424A1 (en)
PL (1) PL204733B1 (en)
PT (1) PT1326585E (en)
RS (1) RS50495B (en)
SA (1) SA01220518B1 (en)
SI (1) SI1326585T2 (en)
SK (1) SK285841B6 (en)
TW (1) TWI283180B (en)
UA (1) UA75375C2 (en)
UY (1) UY26960A1 (en)
WO (1) WO2002030390A2 (en)
ZA (1) ZA200301349B (en)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3477A1 (en) * 2000-10-12 2002-04-18
US6443152B1 (en) * 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
JP2004538267A (en) * 2001-05-25 2004-12-24 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト Combination of dopamine D2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airway disease and other inflammatory diseases
US20030070679A1 (en) * 2001-06-01 2003-04-17 Boehringer Ingelheim Pharma Kg Capsules containing inhalable tiotropium
US20030008001A1 (en) * 2001-06-13 2003-01-09 Boehringer Ingelheim Pharma Kg Process for cleaning hard gelatine capsules
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
DE10141376A1 (en) * 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Process for the preparation of inhalable powders
DE10141377A1 (en) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Scattering process for the production of powder formulations
US7309707B2 (en) * 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
US7244415B2 (en) * 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
CA2479919C (en) * 2002-04-04 2011-05-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder formulations suitable for inhalation
GB0219513D0 (en) 2002-08-21 2002-10-02 Norton Healthcare Ltd Inhalation compositions including coarse carrier
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
JP4744876B2 (en) * 2002-08-21 2011-08-10 ノートン・ヘルスケアー リミテッド Method for producing a dry powder inhalation composition
US20050158248A1 (en) * 2002-08-21 2005-07-21 Xian-Ming Zeng Method of preparing dry powder inhalation compositions
KR101369631B1 (en) * 2002-08-21 2014-03-05 노턴 헬스케어 리미티드 Inhalation composition
DE10255387A1 (en) * 2002-11-28 2004-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg New tiotropium-containing powder formulation for inhalation
US7763280B2 (en) 2002-11-28 2010-07-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropium containing powder formulation for inhalation
DE10351663A1 (en) * 2002-12-20 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Stable, accurately dosable inhalable powder medicament for treating asthma or chronic obstructive pulmonary disease, containing tiotropium, specific form of salmeterol xinafoate and auxiliary
DE10317461A1 (en) 2003-04-16 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Preparing microparticles labeled with technetium, useful as powders for inhalation, e.g. to study deposition of pharmaceuticals, such as anticholinergic agents, involves incubation with solution of technetium salt
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
US7462367B2 (en) 2003-07-11 2008-12-09 Boehringer Ingelheim International Gmbh Anticholinergic powder formulations for inhalation
DE10331350A1 (en) * 2003-07-11 2005-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalation powder useful for treating respiratory diseases comprises a 9,9-dimethyl-7-(2,2-diphenylpropionyloxy)-3-oxa-9-azatricyclononane salt and a finely divided excipient
DE602004031459D1 (en) 2003-09-02 2011-03-31 Norton Healthcare Ltd METHOD FOR PRODUCING A MEDICAMENT
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
PL2067779T3 (en) 2003-11-03 2013-09-30 Boehringer Ingelheim Int Tiotropium salts, method for their production and medicinal formulas containing them
KR20060102561A (en) 2003-11-03 2006-09-27 베링거 인겔하임 인터내셔날 게엠베하 Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same
AU2004294890B2 (en) * 2003-12-03 2010-08-26 Boehringer Ingelheim International Gmbh Pre-metered dry powder inhaler for moisture-sensitive medicaments
DE102004048389A1 (en) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Modification of surfaces of lactose as adjuvant for use with powder inhalants
CN101155590A (en) 2005-02-10 2008-04-02 葛兰素集团有限公司 Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
GB0507835D0 (en) * 2005-04-18 2005-05-25 Solexa Ltd Method and device for nucleic acid sequencing using a planar wave guide
ES2393794T3 (en) 2005-05-02 2012-12-28 Boehringer Ingelheim International Gmbh New crystalline forms of tiotropium bromide
DE102005059602A1 (en) 2005-12-14 2007-06-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Micronization process
EP2011538B1 (en) 2007-07-06 2016-02-17 Vectura Delivery Devices Limited Inhaler
US20100255307A1 (en) * 2007-07-27 2010-10-07 Cargill Inc. Micronization of polyols
EP2082771A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082766A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Blister Strip Coil Forming
EP2082767A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082768A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
EP2082772A1 (en) 2008-01-24 2009-07-29 Vectura Delivery Devices Limited Inhaler
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
EP2662027B1 (en) 2008-05-09 2017-09-27 Holaira, Inc. Systems, assemblies, and methods for treating a bronchial tree
JP2011529135A (en) * 2008-07-24 2011-12-01 レール・リキード−ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード Heteroleptic cyclopentadienyl transition metal precursor for the deposition of transition metal containing films
TWI491416B (en) * 2008-12-24 2015-07-11 Daiichi Sankyo Co Ltd A dry powder pharmaceutical composition for inhalation
GB0918450D0 (en) 2009-10-21 2009-12-09 Innovata Ltd Composition
US9649153B2 (en) 2009-10-27 2017-05-16 Holaira, Inc. Delivery devices with coolable energy emitting assemblies
WO2011060200A1 (en) 2009-11-11 2011-05-19 Innovative Pulmonary Solutions, Inc. Systems, apparatuses, and methods for treating tissue and controlling stenosis
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
US9259376B2 (en) 2010-06-03 2016-02-16 Sima Patent Ve Lisanslama Hizmetleri Ltd. Sti. Process for dry powder formulations
TR201007251A2 (en) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Calcium channel blocker formulation.
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
ES2701525T3 (en) 2014-07-09 2019-02-22 Arven Ilac Sanayi Ve Ticaret As A procedure for the preparation of formulations for inhalation
PL3175842T3 (en) 2015-12-03 2020-06-29 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Dry powder mixing process
EP3826620A4 (en) * 2018-07-12 2023-03-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising dopamine agonists
WO2022146255A1 (en) * 2020-12-31 2022-07-07 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi A process for the preparation of dry powder compositions for inhalation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3860618A (en) 1967-08-08 1975-01-14 Philip Saxton Hartley Chromone
US3957965A (en) 1967-08-08 1976-05-18 Fisons Limited Sodium chromoglycate inhalation medicament
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
BE891013A (en) † 1980-11-05 1982-05-05 Fisons Ltd PHARMACEUTICAL COMPOSITIONS
JPS60150823A (en) * 1984-01-17 1985-08-08 Satake Eng Co Ltd Grain mixing apparatus
JPH0439388A (en) * 1990-06-04 1992-02-10 Teijin Ltd Method for mixing earth and sand with fibrous material
DE4140689B4 (en) * 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalable powders and process for their preparation
JPH06198156A (en) * 1993-01-06 1994-07-19 Nagasaki Pref Gov Atomizing and laminating mixer
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (en) * 1994-07-16 1996-01-18 Asta Medica Ag Formulation for inhalation application
EP1131059B1 (en) * 1998-11-13 2003-03-05 Jago Research Ag Dry powder for inhalation
GB9902689D0 (en) 1999-02-08 1999-03-31 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
NZ525781A (en) 2004-11-26
MEP42708A (en) 2011-02-10
HK1060522A1 (en) 2004-08-13
JP2004510806A (en) 2004-04-08
US6585959B2 (en) 2003-07-01
ATE319422T1 (en) 2006-03-15
MY155912A (en) 2015-12-15
BG107673A (en) 2003-11-28
USRE38912E1 (en) 2005-12-06
CA2425005A1 (en) 2003-04-04
CN1269470C (en) 2006-08-16
HU229512B1 (en) 2014-01-28
NO20031692D0 (en) 2003-04-11
CY1105037T1 (en) 2010-03-03
PL362511A1 (en) 2004-11-02
PL204733B1 (en) 2010-02-26
BG66194B1 (en) 2012-01-31
EP1326585A2 (en) 2003-07-16
RS50495B (en) 2010-03-02
WO2002030390A2 (en) 2002-04-18
EE200300170A (en) 2003-06-16
SI1326585T2 (en) 2011-01-31
EE05146B1 (en) 2009-04-15
ES2259046T3 (en) 2006-09-16
ZA200301349B (en) 2004-06-30
MXPA03003219A (en) 2004-12-03
IL154919A0 (en) 2003-10-31
SI1326585T1 (en) 2006-06-30
UY26960A1 (en) 2002-06-20
HRP20030277B1 (en) 2011-09-30
CN1469733A (en) 2004-01-21
ME02762B (en) 2011-05-10
US20020106332A1 (en) 2002-08-08
EG24478A (en) 2009-08-03
DK1326585T4 (en) 2011-01-10
EA004689B1 (en) 2004-06-24
JP4986369B2 (en) 2012-07-25
WO2002030390A3 (en) 2002-06-27
YU27403A (en) 2006-03-03
BR0114316A (en) 2003-08-26
IL154919A (en) 2011-01-31
HUP0301268A3 (en) 2005-05-30
EP1326585B1 (en) 2006-03-08
DE50109178D1 (en) 2006-05-04
AR034166A1 (en) 2004-02-04
SK4372003A3 (en) 2003-07-01
CA2425005C (en) 2008-08-05
NO20031692L (en) 2003-06-06
HUP0301268A2 (en) 2003-10-28
SA01220518B1 (en) 2006-12-10
HRP20030277A2 (en) 2005-02-28
AU2002218220B2 (en) 2006-06-15
KR100849837B1 (en) 2008-08-01
KR20030051706A (en) 2003-06-25
AU1822002A (en) 2002-04-22
DK1326585T3 (en) 2006-05-22
UA75375C2 (en) 2006-04-17
JP2009197025A (en) 2009-09-03
TWI283180B (en) 2007-07-01
CZ300022B6 (en) 2009-01-14
ES2259046T5 (en) 2011-02-28
EA200300429A1 (en) 2003-10-30
NO333719B1 (en) 2013-09-02
PT1326585E (en) 2006-05-31
EP1326585B2 (en) 2010-09-29
SK285841B6 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
PE20020424A1 (en) PROCEDURE FOR THE PREPARATION OF POWDER FORMULATIONS
HRP20141086T1 (en) Pesticide composition potentiated in efficacy and method for potentiating the efficacy of pesticidal active ingredients
CL2015001973A1 (en) (divisional sol. 1567-2013) combinations of active ingredients comprising pyridylethylbenzamides and other active ingredients.
ES2194480T3 (en) ORAL PHARMACEUTICAL PREPARATION OF AN ANTIFUNGIC ACTIVITY COMPOUND AND PROCEDURE FOR PREPARATION.
EP2286793A3 (en) Pharmaceutical formulations comprising cannabidiol
ES2422655T3 (en) Enhanced immediate release formulations of topiramate
NZ515230A (en) Fast-dispersing dosage forms containing fish gelatin
ATE366568T1 (en) AEROSOL FORMULATIONS OF SALMETEROL XINAFOATE
CO5580735A2 (en) COMPOSITION FOR THE TREATMENT OF THE HAIR THAT INCLUDES COMPOUND PARTICLES OF CLAY AND A LOADED ORGANIC MOLECULA
UY28342A1 (en) NEW COMPOUNDS
AR015524A1 (en) STABLE FORMULATION OF OXIPLATIN SOLUTION, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCESS FOR PREPARATION, PHARMACEUTICAL PRODUCT CONTAINING IT AND A METHOD FOR STABILIZING AN OXALIPLATIN SOLUTION.
AR007827A1 (en) 3-UREIDO-PIRIDOFURANOS y -PIRIDOTIOFENOS, PROCEDURE FOR ITS PREPARATION, COMPOSITION THAT UNDERSTANDS THEM AND USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES.
ATE315930T1 (en) ENCAPSULATING A TOXIC CORE INTO A NON-TOXIC AREA IN AN ORAL DOSAGE FORM
MX2009003235A (en) Oral compositions containing gel networks.
DK0868910T3 (en) Use of Redispersible Polymer Powders or Polymer Granules as Binders for Preparation of Solid Pharmaceutical Dispersing Forms
CR7500A (en) DOSAGE FORMS OF AZITROMICIDE WITH REDUCED SIDE EFFECTS
BR0110141A (en) Improvements in or relating to formulations for use in inhaler devices
AR065970A2 (en) A SOLID ORAL PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF METFORMIN AND GLIBENCLAMIDE AND USE OF SUCH COMPOSITION
CO4130180A1 (en) SKIN CARE COMPOSITIONS CONTAINING A WATER EMULSION IN OIL AND A RETINOID
UY29701A1 (en) LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
AR034898A1 (en) CRYSTAL COMPOSITION CONTAINING ESCITALOPRAM
NO970361L (en) Sprayable film-forming system that releases active substances for use on plants
MXPA05010196A (en) Formulations comprising an active ingredient and cocoa powder and use thereof.
HUP0401224A2 (en) Process for preparing pharmaceutical compositions for use with soft gelatin formulations
DK1289502T3 (en) Microemulsion preconcentrate, microemulsion and use of a composition

Legal Events

Date Code Title Description
FG Grant, registration